CVRx announces Medicare win for Barostim therapy
July 16, 2025
CVRx (Nasdaq:CVRX) announced today that CMS proposed to keep its Barostim implant procedure within a certain payment class.
CVRx (Nasdaq:CVRX) announced today that CMS proposed to keep its Barostim implant procedure within a certain payment class.
Non-Invasive Histotripsy Treatment Now Accessible to 7 Million Blue Cross Blue Shield Highmark Members Across U.S.
The CE Mark approval of the VitalFlow™ ECMO System marks a significant advancement in extracorporeal life support, delivering enhanced precision and control for managing critically ill cardiac and respiratory patients.
Johnson & Johnson MedTech (NYSE: JNJ)+
today announced FDA approval for an update to its Varipulse platform’s irrigation flow rate.
TEL AVIV, Israel, July 10, 2025 /PRNewswire/ — Scopio Labs, a trailblazer in Full-Field Digital Cell Morphology, today announced another significant milestone: its fourth U.S. Food and Drug Administration (FDA) clearance (K243144). This latest clearance introduces powerful new Decision Support System (DSS) features to its X100 and X100HT platforms and Peripheral Blood Smear (PBS) Application, further transforming the way laboratories analyze red blood cell (RBC) morphology and identify platelet clumps in peripheral blood smears.
Innovative software platform leverages artificial intelligence to personalize therapy decisions and improve clinical outcomes for prostate cancer patients.
AI-Powered 3D Surgical Planning Tool Advances Precision Breast Cancer Surgery with Latest Regulatory Milestone
Intuitive Surgical (Nasdaq: ISRG)+
announced today that the FDA cleared the latest advanced energy instrumentation for its da Vinci systems.
JERSEY CITY, N.J. and OR YEHUDA, Israel, July 10, 2025 /PRNewswire/ — Synchrony Medical, a medical technology company dedicated to advancing respiratory care, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its LibAirty™ Airway Clearance System in the United States.
OREM, Utah, July 10, 2025 /PRNewswire/ — Dymicron®, a privately held medical device company pioneering advanced spinal technologies, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to begin a pivotal clinical study of the Triadyme®–C cervical artificial disc.